Successful Development of Bacteriocins into Therapeutic Formulation for Treatment of MRSA Skin Infection in a Murine Model-Reference-Cited by-同舟云学术

Successful Development of Bacteriocins into Therapeutic Formulation for Treatment of MRSA Skin Infection in a Murine Model

Published:2020-11-17 Issue:12 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ovchinnikov Kirill V.¹^ORCID,Kranjec Christian¹,Thorstensen Tage²,Carlsen Harald¹,Diep Dzung B.¹^ORCID

Affiliation:

1. Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway

2. Department of Plant Molecular Biology, Norwegian Institute of Bioeconomy Research, Ås, Norway

Abstract

The emergence of antibiotic-resistant pathogens has caused a serious worldwide problem in infection treatment in recent years. One of the pathogens is methicillin-resistant Staphylococcus aureus (MRSA), which is a major cause of skin and soft tissue infections. Alternative strategies and novel sources of antimicrobials to solve antibiotic resistance problems are urgently needed. In this study, we explored the potential of two broad-spectrum bacteriocins, garvicin KS and micrococcin P1, in skin infection treatments.

Funder

Norges Forskningsråd

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00829-20

Reference48 articles.

1. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

2. The antibiotic resistance crisis, with a focus on the United States

3. The Antimicrobial Resistance Crisis: Causes, Consequences, and Management